US20210323981A1 - Free amino compounds for the treatment and prophylaxis of bacterial infection - Google Patents

Free amino compounds for the treatment and prophylaxis of bacterial infection Download PDF

Info

Publication number
US20210323981A1
US20210323981A1 US17/326,241 US202117326241A US2021323981A1 US 20210323981 A1 US20210323981 A1 US 20210323981A1 US 202117326241 A US202117326241 A US 202117326241A US 2021323981 A1 US2021323981 A1 US 2021323981A1
Authority
US
United States
Prior art keywords
methyl
amino
pyrido
indol
naphthyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/326,241
Other languages
English (en)
Inventor
Hong Shen
Xuefei Tan
Chengang Zhou
Mingwei Zhou
Yimin Hu
Houguang Shi
Fabian Dey
Yongqiang Liu
Xiao DING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoffmann La Roche Inc
Original Assignee
Hoffmann La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche Inc filed Critical Hoffmann La Roche Inc
Publication of US20210323981A1 publication Critical patent/US20210323981A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to organic compounds useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of DNA gyrase and/or topoisomerase IV useful for treatment and/or prophylaxis of bacterial infection.
  • DNA gyrase and topoisomerase IV bacterial type IIA topoisomerases
  • DNA Gyrase controls DNA supercoiling and relieves topological stress that occurs when the DNA strands are untwisted such as during replication.
  • Topoisomerase IV primarily resolves linked chromosome dimers at the conclusion of DNA replication.
  • Both enzymes can introduce double stranded DNA breaks; pass a second DNA strand through the break and rejoining the broken strands. The activity of both enzymes is driven by the binding and hydrolysis of ATP.
  • Bacterial DNA gyrase consists of two A (GyrA) and two B (GyrB) subunits. Binding and cleavage of the DNA is associated with GyrA, whereas ATP is bound and hydrolyzed by GyrB.
  • Bacterial Topoisomerase IV is also a hetero-tetramer that consists of two C (ParC) and two E (ParE) subunits. The latter subunits bind ATP like GyrB in order to supply energy necessary for catalytic turnover of the enzymes.
  • the present invention relates to novel compounds of formula (I),
  • novel compounds of formula (I) are novel compounds of formula (I), their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula (I) for the treatment or prophylaxis of bacterial infection.
  • the use of compounds of formula (I) as DNA gyrase and/or topoisomerase IV inhibitors is also one of the objections of present invention.
  • the compounds of formula (I) showed superior anti-bacterial activity, good solubility, good CC 50 profiles, improved microsomal stability and/or improved PK profile.
  • C 1-6 alkyl denotes a saturated, linear or branched chain alkyl group containing 1 to 6, particularly 1 to 4 carbon atoms, for example methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl and the like.
  • Particular “C 1-6 alkyl” groups are methyl, ethyl and propyl.
  • halogen and “halo” are used interchangeably herein and denote fluoro, chloro, bromo, or iodo.
  • haloC 1-6 alkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by same or different halogen atoms, particularly fluoro atom.
  • haloC 1-6 alkyl include monofluoro-, difluoro- or trifluoro-methyl, -ethyl or -propyl, for example 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl, difluoromethyl, trifluoromethyl and trifluoroethyl.
  • C 3-7 cycloalkyl denotes a saturated monocyclic or bicyclic carbon ring containing from 3 to 7 carbon atoms, particularly from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[1.1.1]pentanyl and the like.
  • Particular “C 3-7 cycloalkyl” group is cyclopropyl.
  • the term “rel” refers to relative configuration, for example, Example 1.13, 6-[5-Cyano-6-fluoro-8-(methylamino)-4-[rel-(3aR,4R,6aS)-4-amino-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]-9H-pyrido[2,3-b]indol-3-yl]-1-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
  • pharmaceutically acceptable salts denotes salts which are not biologically or otherwise undesirable.
  • Pharmaceutically acceptable salts include both acid and base addition salts.
  • pharmaceutically acceptable acid addition salt denotes those pharmaceutically acceptable salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and organic acids selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, maloneic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene
  • pharmaceutically acceptable base addition salt denotes those pharmaceutically acceptable salts formed with an organic or inorganic base.
  • acceptable inorganic bases include sodium, potassium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts.
  • Salts derived from pharmaceutically acceptable organic nontoxic bases includes salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, N-ethylpiperidine, and polyamine resins.
  • substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, trieth
  • therapeutically effective amount denotes an amount of a compound or molecule of the present invention that, when administered to a subject, (i) treats or prevents the particular disease, condition or disorder, (ii) attenuates, ameliorates or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition or disorder described herein.
  • the therapeutically effective amount will vary depending on the compound, the disease state being treated, the severity of the disease treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors.
  • composition denotes a mixture or solution comprising a therapeutically effective amount of an active pharmaceutical ingredient together with pharmaceutically acceptable excipients to be administered to a mammal, e.g., a human in need thereof.
  • the present invention relates to a compound of formula (I),
  • R 1 is C 1-6 alkyl
  • R 2 is halogen
  • R 3 is halogen or cyano
  • R 4 is 1,3,4,5,6,6a-hexahydrocyclopenta[c]pyrrolyl substituted by amino
  • a further embodiment of present invention is (ii) a compound of formula (I) according to (i), wherein
  • a further embodiment of present invention is (iii) a compound of formula (I) according to (i) or (ii), or a pharmaceutically acceptable salt thereof, wherein R 4 is azaspiro[2.4]heptanyl substituted by amino; pyrrolidinyl substituted once or twice by substituents independently selected from amino, aminoC 1-6 alkyl, aminoC 3-7 cycloalkyl, haloC 1-6 alkyl and halogen.
  • a further embodiment of present invention is (iv) a compound of formula (I) according to any one of (i) to (iii), or a pharmaceutically acceptable salt thereof, wherein R 4 is aminoazaspiro[2.4]heptanyl; aminocyclopropylpyrrolidinyl; amino(trifluoromethyl)pyrrolidinyl; aminomethyl(fluoro)pyrrolidinyl; aminomethylpyrrolidinyl; or aminopyrrolidinyl.
  • a further embodiment of present invention is (v) a compound of formula (I) according to any one of (i) to (iv), or a pharmaceutically acceptable salt thereof, wherein R 5 is methyl.
  • a further embodiment of present invention is (vi) a compound of formula (I) according to any one of (i) to (v), wherein
  • a further embodiment of present invention is (vii) a compound of formula (I) according to any one of (i) to (vi),wherein
  • the compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds as well as their starting materials are provided in the schemes below and in the examples. All substituents, in particular, R 1 to R 6 are as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry.
  • X 1 , X 2 , X 3 and X 4 are halogen.
  • X 1 , X 2 , X 3 and X 4 are halogen.
  • compound of formula (Ig) can be prepared according to Scheme 2. Coupling of the compound of formula (Id) with di-halogenated pyridine can be achieved using palladium catalyst and phosphine ligands to give compound of formula (Ik). Cyclization of compound of formula (Ik) using palladium catalyst and phosphine ligands gives compound of formula (Im). Compound of formula (Im) can be subject to halogenation using halogenating reagent, such as NCS, NBS or NIS, to give compound of formula (If), which subsequently undergoes oxidation of the pyridine followed by halogenation, such as treatment of POCl 3 or POBr 3 .
  • halogenating reagent such as NCS, NBS or NIS
  • compound of formula (If) can be obtained by treatment of compound of formula (If) (when R 3 is H) with halogenating reagent, such as NBS, to give compound of formula (If) (when R 3 is halogen, in particular bromo).
  • halogenating reagent such as NBS
  • compound of formula (If) can also be obtained by converting compound of formula (If) (when R 3 is halogen, in particular bromo) to compound of formula (If) (when R 3 is CN) via palladium mediated substitution or nucleophilic substitution.
  • Compound of formula (Ig) can then be obtained through oxidation of the pyridine of compound of formula (If) followed by halogenation, such as treatment of POCl 3 or POBr 3 .
  • X 3 and X 4 are halogen, X 5 are halogen or OTf; Q 1 and Q 2 are boronic acids or esters.
  • Compound of formula (I) can be prepared according to Scheme 3. Introducing R 4 to compound of formula (Ig) can be achieved either through nucleophilic substitution with amine and a base for certain C—N bond formation (with R 4 bearing a nucleophilic N), or a Buchwald-Hartwig Cross Coupling Reaction for certain C—N bond formation (with R 4 bearing a basic N), to give compound of formula (Ih). Further coupling of compound of formula (Ih) with compound of formula (Io) to give compound of formula (Ii) can be achieved using a palladium catalyzed Suzuki coupling. Chiral separation can be achieved on compound of formula (Ih) or compound of formula (Ii).
  • Some special compound of formula (Ii) need to reverse the Suzuki coupling for C—C bond formation by converting compound of formula (Ih) to compound of formula (Ij) as a boronic ester or boronic acid then coupling with compound of formula (Ip). Ester hydrolysis such as NaOH in ethanol followed by deprotection of compound of formula (Ii) in the presence of an acid, such as trifluoroacetic acid, then affords compound of formula (I).
  • This invention also relates to a process for the preparation of a compound of formula (I) comprising the reaction of compound of formula (Ii),
  • an acid which can be for example trifluoroacetic acid
  • R 1 to R 6 are defined above.
  • a compound of formula (I) when manufactured according to the above process is also an object of the invention.
  • compositions or medicaments containing the compounds of the invention and a therapeutically inert carrier, diluent or excipient, as well as methods of using the compounds of the invention to prepare such compositions and medicaments.
  • compounds of formula (I) may be formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form.
  • the pH of the formulation depends mainly on the particular use and the concentration of compound, but preferably ranges anywhere from about 3 to about 8.
  • a compound of formula (I) is formulated in an acetate buffer, at pH 5.
  • the compounds of formula (I) are sterile.
  • the compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution.
  • compositions are formulated, dosed, and administered in a fashion consistent with good medical practice.
  • Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
  • the “effective amount” of the compound to be administered will be governed by such considerations, and is the minimum amount necessary to reduced bacterial load or improve host survival through the inhibition of bacterial DNA gyrase and/or Topoisomerase IV. For example, such amount may be below the amount that is toxic to normal cells, or the mammal as a whole.
  • the pharmaceutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.1 to 1000 mg/kg, alternatively about 1 to 100 mg/kg of patient body weight per day.
  • oral unit dosage forms such as tablets and capsules, preferably contain from about 5 to about 5000 mg of the compound of the invention.
  • the compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration.
  • Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
  • the compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc.
  • Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents.
  • a typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient.
  • Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C., et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005.
  • the formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).
  • buffers stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing
  • An example of a suitable oral dosage form is a tablet containing about 10 to 500 mg of the compound of the invention compounded with about 40 to 400 mg anhydrous lactose, about 5 to 50 mg sodium croscarmellose, about 5 to 50 mg polyvinylpyrrolidone (PVP) K30, and about 1 to 10 mg magnesium stearate.
  • the powdered ingredients are first mixed together and then mixed with a solution of the PVP.
  • the resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using conventional equipment.
  • An example of an aerosol formulation can be prepared by dissolving the compound, for example 5 to 1000 mg) of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g. a salt such sodium chloride, if desired.
  • the solution may be filtered, e.g., using a 0.2 micron filter, to remove impurities and contaminants.
  • An embodiment therefore, includes a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient.
  • Another embodiment includes a pharmaceutical composition comprising a compound of formula (I) for use in the treatment and/or prophylaxis of bacterial infections.
  • the compounds of this invention may be administered, as part of a single or multiple dosage regimen, orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir.
  • parenteral as used includes subcutaneous, intracutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
  • the pharmaceutical compositions of the invention will be administered from about 1 to 5 times per day or alternatively, as a continuous infusion upon improvement of a patient's condition.
  • the compounds of the invention are useful for treatment and/or prophylaxis of bacterial infection in humans or other animals by administering to the subject in need of a therapeutically effective amount of compound of formula (I), or a pharmaceutically acceptable salt, or enantiomer or diastereomer thereof.
  • the compounds and methods of the invention are particularly well suited for human patients infected by pathogens that include Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa.
  • bacterial organisms that may also be controlled by the compounds of the invention include, but not limited to, the following Gram-Positive and Gram-Negative organisms: Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Enterobacter spp. species, Proteus spp. species, Serratia marcescens, Staphylococcus aureus, Coag. Neg.
  • Staphylococci Haemophilus influenzae, Bacillus anthraces, Mycoplasma pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Chlamydia trachomatis, Legionella pneumophila, Mycobacterium tuberculosis, Helicobacter pylori, Staphylococcus saprophyticus, Staphylococcus epidermidis, Francisella tularensis, Yersinia pestis, Clostridium difficile, Bacteroides spp.
  • Neisseria gonorrhoeae Neisseria meningitidis, Burkholderia pseudomallei, Burkholderia mallei, Borrelia burgdorferi, Mycobacterium avium complex, Mycobacterium abscessus, Mycobacterium kansasii, E. coli and Mycobacterium ulcerans.
  • bacterial infections may include, but not limited to, upper respiratory infections, lower respiratory infections, ear infections, pleuropulmonary and bronchial infections, complicated urinary tract infections, uncomplicated urinary tract infections, intra-abdominal infections, cardiovascular infections, a blood stream infection, sepsis, bacteremia, CNS infections, skin and soft tissue infections, GI infections, bone and joint infections, genital infections, eye infections, or granulomatous infections.
  • bacterial infections include, but not limited to, uncomplicated skin and skin structure infections (uSSSI), complicated skin and skin structure infections (cSSSI), catheter infections, pharyngitis, sinusitis, otitis extema, otitis media, bronchitis, empyema, pneumonia, community-acquired bacterial pneumoniae (CABP), hospital-acquired pneumonia (HAP), hospital-acquired bacterial pneumonia, ventilator-associated pneumonia (VAP), diabetic foot infections, vancomycin resistant enterococci infections, cystitis and pyelonephritis, renal calculi, prostatitis, peritonitis, complicated intra-abdominal infections (cIAI) and other inter-abdominal infections, dialysis-associated peritonitis, visceral abscesses, endocarditis, myocarditis, pericarditis, transfusion-associated sepsis, meningitis, encephalitis, brain abscess
  • the invention relates to the use of a compound of formula (I) for the treatment and/or prophylaxis of bacterial infection.
  • the invention relates to the use of a compound of formula (I) for the preparation of a medicament for the treatment and/or prophylaxis of bacterial infection.
  • Another embodiment includes a method for the treatment or prophylaxis of bacterial infection which method comprises administering an effective amount of a compound of formula (I), or pharmaceutically acceptable salt, or enantiomer or diastereomer thereof.
  • Acidic condition A: 0.1% formic acid and 1% acetonitrile in H 2 O; B: 0.1% formic acid in acetonitrile;
  • Mass spectra generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion (M+H) + .
  • the titled compound was synthesized according to the following scheme:
  • reaction mixture was stirred at 160° C. for 6 h before it was cooled back to room temperature and poured into water (100 mL).
  • the mixture was extracted with EtOAc (200 mL) and the organic layer was collected and washed with water (50 mL) two times, brine (30 mL) two times, and dried over anhy. sodium sulfate.
  • the titled compound was synthesized according to the following scheme:
  • the titled compound was synthesized according to the following scheme:
  • the titled compound was synthesized according to the following scheme:
  • the titled compound was synthesized according to the following scheme:
  • the titled compound was synthesized according to the following scheme:
  • the titled compound was synthesized according to the following scheme:
  • Step (a) Preparation of tert-butyl N-[4-[3-[1-(tert-butoxycarbonylamino)cyclopropyl]pyrrolidin-1-yl]-3-chloro-5,6-difluoro-9H-pyrido[2,3-b]indol-8-yl]-N-methyl-carbamate
  • Step (b) Preparation of ethyl 6-[4-[3-[1-(tert-butoxycarbonylamino)cyclopropyl]pyrrolidin-1-yl]-8-[tert-butoxycarbonyl(methyl)amino]-5,6-difluoro-9H-pyrido[2,3-b]indol-3-yl]-1-methyl-4-oxo-1,8-naphthyridine-3-carboxylate
  • Step (c) Preparation of 6-[4-[3-[1-(tert-butoxycarbonylamino)cyclopropyl]pyrrolidin-1-yl]-8-[tert-butoxycarbonyl(methyl)amino]-5,6-difluoro-9H-pyrido[2,3-b]indol-3-yl]-1-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
  • Step (b) Preparation of ethyl 6-[4-[2-(tert-butoxycarbonylamino)-5-azaspiro[2.4]heptan-5-yl]-8-[tert-butoxycarbonyl(methyl)amino]-5,6-difluoro-9H-pyrido[2,3-b]indol-3-yl]-1-methyl-4-oxo-1,8-naphthyridine-3-carboxylate
  • Step (c) Preparation of trans-ethyl 6-[4-[2-(tert-butoxycarbonylamino)-5-azaspiro[2.4]heptan-5-yl]-8-[tert-butoxycarbonyl(methyl)amino]-5,6-difluoro-9H-pyrido[2,3-b]indol-3-yl]-1-methyl-4-oxo-1,8-naphthyridine-3-carboxylate and cis-ethyl 6-[4-[2-(tert-butoxycarbonylamino)-5-azaspiro[2.4]heptan-5-yl]-8-[tert-butoxycarbonyl(methyl)amino]-5,6-difluoro-9H-pyrido[2,3-b]indol-3-yl]-1-methyl-4-oxo-1,8-naphthyridine-3-carboxylate
  • Step (b) Preparation of tert-butyl(4-((1S,3R)-1-((tert-butoxycarbonyl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-chloro-5,6-difluoro-9H-pyrido[2,3-b]indol-8-yl)(methyl)carbamate
  • Step (c) Preparation of ethyl 6-[4-[(2R,3R)-2-(tert-butoxycarbonylamino)-5-azaspiro[2.4]heptan-5-yl]-8-[tert-butoxycarbonyl(methyl)amino]-5,6-difluoro-9H-pyrido[2,3-b]indol-3-yl]-1-methyl-4-oxo-1,8-naphthyridine-3-carboxylate
  • the mixture solution was then stirred at 70° C. for 16 h under Ar. After cooled back to the r.t., the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL) three times. Combined organics were washed with brine (20 mL), dried with anhy.
  • Step (a) Preparation of cis-tert-butyl N-[3-bromo-4-[2-(tert-butoxycarbonylamino)-5-azaspiro[2.4]heptan-5-yl]-5-chloro-6-fluoro-9H-pyrido[2,3-b]indol-8-yl]-N-methyl-carbamate and trans-tert-butyl N-[3-bromo-4-[2-(tert-butoxycarbonylamino)-5-azaspiro[2.4]heptan-5-yl]-5-chloro-6-fluoro-9H-pyrido[2,3-b]indol-8-yl]-N-methyl-carbamate
  • tert-butyl (3-bromo-4,5-dichloro-6-fluoro-9H-pyrido[2,3-b]indol-8-yl) (methyl)carbamate 900 mg, 1.94 mmol, Intermediate A5
  • tert-butyl 5-azaspiro[2.4]heptan-1-ylcarbamate 500 mg, 2.36 mmol
  • DIPEA 750 mg, 5.80 mmol
  • Step (b) Preparation of tert-butyl(3-bromo-4-((1S,3R)-1-((tert-butoxycarbonyl)amino)-5-azaspiro[2.4]heptan-5-yl)-5-chloro-6-fluoro-9H-pyrido[2,3-b]indol-8-yl) (methyl)carbamate and tert-butyl(3-bromo-4-((1R,3S)-1-((tert-butoxycarbonyl)amino)-5-azaspiro[2.4]heptan-5-yl)-5-chloro-6-fluoro-9H-pyrido[2,3-b]indol-8-yl) (methyl)carbamate and tert-butyl(3-bromo-4-((1R,3R)-1-((tert-butoxycarbonyl)amino)-5-azaspiro[2.4]heptan-5-
  • Cis-tert-butyl N-[3-bromo-4-[2-(tert-butoxycarbonylamino)-5-azaspiro[2.4]heptan-5-yl]-5-chloro-6-fluoro-9H-pyrido[2,3-b]indol-8-yl]-N-methyl-carbamate (710.0 mg, 1.11 mmol) was subject to chiral SFC separation.
  • Step (c) Preparation of ethyl 6-[4-[(2R,3R)-2-(tert-butoxycarbonylamino)-5-azaspiro[2.4]heptan-5-yl]-8-[tert-butoxycarbonyl(methyl)amino]-5-chloro-6-fluoro-9H-pyrido[2,3-b]indol-3-yl]-1-methyl-4-oxo-1,8-naphthyridine-3-carboxylate
  • reaction mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL) three times. Combined organics were washed with brine (20 mL), dried over anhy.
  • Step (b) Preparation of tert-butyl N-[4-[(2S,3R)-2-(tert-butoxycarbonylamino)-5-azaspiro[2.4]heptan-5-yl]-3-chloro-5-cyano-6-fluoro-9H-pyrido[2,3-b]indol-8-yl]-N-methyl-carbamate
  • Step (c) Preparation of ethyl 6-[4-[(2S,3R)-2-(tert-butoxycarbonylamino)-5-azaspiro[2.4]heptan-5-yl]-8-[tert-butoxycarbonyl(methyl)amino]-5-cyano-6-fluoro-9H-pyrido[2,3-b]indol-3-yl]-1-methyl-4-oxo-1,8-naphthyridine-3-carboxylate
  • Step (a) Preparation of cis-tert-butyl N-[4-[2-(tert-butoxycarbonylamino)-5-azaspiro[2.5]octan-5-yl]-3-chloro-5,6-difluoro-9H-pyrido[2,3-b]indol-8-yl]-N-methyl-carbamate
  • Step (b) Preparation of tert-butyl N-[4-[(2S,3S)-2-(tert-butoxycarbonylamino)-5-azaspiro[2.5]octan-5-yl]-3-chloro-5,6-difluoro-9H-pyrido[2,3-b]indol-8-yl]-N-methyl-carbamate and tert-butyl N-[4-[(2R,3R)-2-(tert-butoxycarbonylamino)-5-azaspiro[2.5]octan-5-yl]-3-chloro-5,6-difluoro-9H-pyrido[2,3-b]indol-8-yl]-N-methyl-carbamate
  • Step (c) Preparation of ethyl 6-[4-[(2R,3R)-2-(tert-butoxycarbonylamino)-5-azaspiro[2.5]octan-5-yl]-8-[tert-butoxycarbonyl(methyl)amino]-5,6-difluoro-9H-pyrido[2,3-b]indol-3-yl]-1-methyl-4-oxo-1,8-naphthyridine-3-carboxylate
  • the assay used a 10-points Iso-Sensitest broth medium to measure quantitatively the in vitro activity of the compounds against S. aureus ATCC29213, K. pneumoniae ATCC 10031, and A. baumannii ATCC17978.
  • Stock compounds in DMSO were serially two-fold diluted (range from 50 to 0.097 ⁇ M final concentration) in 384 wells microtiter plates and inoculated with 49 ⁇ L the bacterial suspension in Iso-Sensitest broth medium to have a final cell concentration of ⁇ 5 ⁇ 10 5 CFU/mL in a final volume/well of 50 ⁇ L/well.
  • Microtiter plates were incubated at 35 ⁇ 2° C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
US17/326,241 2018-11-22 2021-05-20 Free amino compounds for the treatment and prophylaxis of bacterial infection Abandoned US20210323981A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/116868 2018-11-22
CN2018116868 2018-11-22
PCT/EP2019/081760 WO2020104436A1 (fr) 2018-11-22 2019-11-19 Composés aminés libres pour le traitement et la prophylaxie d'une infection bactérienne

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/081760 Continuation WO2020104436A1 (fr) 2018-11-22 2019-11-19 Composés aminés libres pour le traitement et la prophylaxie d'une infection bactérienne

Publications (1)

Publication Number Publication Date
US20210323981A1 true US20210323981A1 (en) 2021-10-21

Family

ID=69143480

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/326,241 Abandoned US20210323981A1 (en) 2018-11-22 2021-05-20 Free amino compounds for the treatment and prophylaxis of bacterial infection

Country Status (5)

Country Link
US (1) US20210323981A1 (fr)
EP (1) EP3883937A1 (fr)
JP (1) JP2022507859A (fr)
CN (1) CN113166174A (fr)
WO (1) WO2020104436A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116406365A (zh) * 2020-10-13 2023-07-07 豪夫迈·罗氏有限公司 用于制备1-甲基-6-[6-R2-5-甲基-8-(甲基氨基)-4-[(3aS,6aS)-5-甲基-2,3,3a,4,6,6a-六氢吡咯并[2,3-c]吡咯-1-基]-9H-吡啶并[2,3-b]吲哚-3-基]-4-氧代-1,8-萘啶-3-甲酸盐酸盐的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018178041A1 (fr) * 2017-03-30 2018-10-04 F. Hoffmann-La Roche Ag Nouveaux composés pyrido[2,3-b]indole pour le traitement et la prophylaxie d'une infection bactérienne

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112204037A (zh) * 2018-05-28 2021-01-08 豪夫迈·罗氏有限公司 用于治疗和预防细菌感染的新氧代喹嗪化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018178041A1 (fr) * 2017-03-30 2018-10-04 F. Hoffmann-La Roche Ag Nouveaux composés pyrido[2,3-b]indole pour le traitement et la prophylaxie d'une infection bactérienne

Also Published As

Publication number Publication date
CN113166174A (zh) 2021-07-23
WO2020104436A1 (fr) 2020-05-28
JP2022507859A (ja) 2022-01-18
EP3883937A1 (fr) 2021-09-29

Similar Documents

Publication Publication Date Title
EP3601282B1 (fr) Nouveaux composés pyrido[2,3-b]indole pour le traitement et la prophylaxie d'une infection bactérienne
EP3802549B1 (fr) Nouveaux composés d'oxoquinolizine pour le traitement et la prophylaxie d'une infection bactérienne
JP6030146B2 (ja) ２−オキソ−オキサゾリジン−３，５−ジイル抗生物質誘導体
EP3887371B1 (fr) Composés aryle pour le traitement et la prophylaxie d'une infection bactérienne
US20210323981A1 (en) Free amino compounds for the treatment and prophylaxis of bacterial infection
US20210221832A1 (en) Substituted pyridoindoles for the treatment and prophylaxis of bacterial infection
US20210309657A1 (en) Tricyclic compounds for the treatment and prophylaxis of bacterial infection
WO2022266425A1 (fr) Dérivés de 3-cyano-quinoléine et leurs utilisations
CA3209599A1 (fr) Derives de pyrazoleamide
JP7531492B2 (ja) 細菌感染症の処置および予防のためのオキソピリド［１，２－ａ］ピリミジン化合物
WO1997031919A1 (fr) Derives d'acide pyridonecarboxylique et leur intermediaires de synthese
WO2023166103A1 (fr) Composés benzamide pour le traitement d'infections bactériennes
JP2024529132A (ja) 抗生物質ピラジノチアジン誘導体及びその調製方法

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED